版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
Capsules
Capsules-CapsulaeEP5.01‘Capsulesaresolidpreparationswithhardorsoftshellsofvariousshapesandcapacities,usuallycontainingasingledoseofactivesubstance.Theyareintendedfororaladministration’.Thecapsuleshellsaremadeofgelatin…..HardCapsules Relativelyeasyproduction. Capsuleshellsavailablefrommanymanufacturers.OftenfilledinDispensary/HospitalSoftCapsules
Specificrooms(humidity&temperature)andequipmentnecessaryforproductionOnlyveryfewContractManufacturersGelatinmanufacture/html/rawmaterials.htmlGelatinmanufactureResult:
Differentiso-electricalpointTypeAratheralkaline(pH6.0–9.5)TypeBratheracidic(pH4.7–5.6)Reason:Hydrolysisofglutamine/asparagineoccursonlyduringthealkalineprocessPropertiesofGelatinAppearance Faintlyyelloworlightyellowish-brown,solid,usually occurringastranslucentsheets,shreds,granulesor powder.Solubility –Swellsincoldwaterandgivesonheatingacolloidal solution –Goodsolubilityinglycerol,propyleneglycol,sorbitol solutionandaceticacid –PartiallysolubleinEtOH-water-mixtures –Insolubleinethanol,etherandotherorganicsolventsSoftCapsules?Multipurposedosageform:eg,oral,rectal,vaginal?Swallow,breakwiththeteeth,suckon(Gelsolets)?Fillingvolumefrom0.1-20mlSoftGelatinCapsules Thethickshellcontainsglyceroland/orsorbitolasplasticiserWatercontent7-8%Higherhygroscopicitythanhardgelatincapsules(plasticiser)HugediversityinformsandcoloursUsedfornonaqueoussolutionsandsuspensionsSize/shapemanufacture1.Swellingofthegelatin2.Additionofplasticisers,antimicrobialpreservatives,sweeteners,colouringmatter3.Castingofgelatinribbons4.Shapingtothedimensionofthedie5.FillingfromdosingpumpdirectlybeforesealingRotary-DieMethod
(Scherer,1933)
AContinuousprocess…/Rotary-Diemethod1Gelatinribbons2Rotarydies3V-notchfiller4Finishedcapsules5Gelatinribbonwithpunchedholes6FeedmaterialOthermethodsTheScherermethodisnottheonlyprocess…..SomemethodsusevacuumfillingSomecanproduceseamlesscapsulesThebasicprinciplesareshownmosteasilyintheScherermethod….Incookingtermsitislikemakingravioli!Advantages/DisadvantagesofSC
SuitablefornonaqueousfillingsExclusionofair(oxygen)assuresstabilityforsensitivedrugs(eg,vitamins)HughdiversityofcoloursandshapesCompliance,drugsafetySurfactants(seams!)andwatercontainingmaterialsnotencapsulatableProductionrequiresspecificenvironmentalconditions(20-30%rH,22°C)SpecialisedcontractmanufacturersreleaseSoftcapsulesgenerallyshowexcellentreleasecharacteristics.Thestomachisdesignedtodigestsoftproteinmateriallikecapsuleshellssothefillingisaccessedveryrapidly.HardGelatinCapsulesInventedin1846CapsuleshellsconsistingoftwoprefabricatedcylindricalsectionsWatercontent10-12%Ingredients: –Gelatin, –colouringagents –opacifiers(TiO2,Fe-oxides)HCmanufactureCommonfaultssizesCapsuleFillingCapsuleFillingofSolidsCapsuleFillingofPelletsCapsuleFillingofPellets
CapsuleFilling–
LiquidFormulationsCapsuleFillingofLiquidsSomePointsonHGC1.Compatibilitywithgelatin Drugswithreactivealdehydegroupsareincompatiblewithgelatin(cross-linking).Hightemperatures,humidityandlightshouldalsobeavoided.
2.Dose Shouldbebetween100–600mg…continued
3.Particlesizeandshape Isometricparticleshavebetterflow properties Particlesizebetween10-150m4.Hygroscopicity Hygroscopicexcipients/drugswillabsorb waterfromthegelatin=>brittleness…continued6.ChoiceoftheCapsule Size:preferablysmall Choiceofcolour: -Identification -Psychologicaleffects:BLUE:cool,calmingRED,ORANGE:stimulating,arousingTabsv.CapsExcipientsforFastReleaseHC
1.Diluents Mannitol Lactose Starch(maize) microcrystallinecellulose2.Lubricants Magnesiumstearate Stearicacid Glycerolmono-stearate3.Flowregulatingagents Aerosil? TalcObjectivesWiththepossibleexceptionofanaestheticgases,medicinalsubstancesaredeliveredtothebodyasformulatedproducts.Aformulatedsubstancecouldalsobecalledadosageform,andconsistsofanActivePharmaceuticalIngredient(API)andvariousexcipients.DosageFormsDosageformsvaryfromrelativelysimplemixtures(asinapowderblendorasolution)totechnologicallycomplexdevicessuchaspatches.Youshouldinsertheresomereferencetoacomprehensivelistingofdosageforms(partofyourpost-lecturestudy).CommonfeaturesDespitethewiderangeofdosageformsthereareseveralcommonfeatures:Shouldbestable–hencecompatibilitybetweentheAPIandtheexcipientsShouldbecapableofconsistentmanufacture(quality–adherencetoaspecification)ShoulddeliveraconsistenteffecttothepatientStabilityDosageformsaremixturesofchemicals–hencetheyareinherentlyunstable.Thequestionisnot‘whetherthesubstancewilldegrade?’but‘Cantherateofdegradationbecontrolled?’StabilityismonitoredbyobservingboththereductionintheAPIcontent,andtheincreaseofadegradationproduct.ControlofstabilityThedosageformhastobeformulatedcorrectlysothatthemaximumshelf-lifeisattained.Degradationoccursthroughacombinationofchemical,physical,andmicrobiologicalprocesses.Theseeffectsarecontrolledbycorrectprocessingandbyselectionofsuitableexcipients.QualityAdherencetoaspecificationisthekeyfeatureinaqualitysystem.Thespecificationisgeneratedduringformulationtrialsandmustreflectaveragemanufacturingconditions.Formulationworkstartsonagram-scale,movesthroughtokilo-scaleandthento100sofkilosortonnes.TechnologicaltransferAsthescaleofworkingisincreasedfromthelabtothepilotplantandthentoproductionscaletheprocessesinvolvedhavetobetransferred.Thereisawealthofdifferencebetweenstirringsomethingina250mLbeakeranddoingthesameoperationto100kgproductThenatureoftheproductaltersasthescaleofworkingchanges.Finalformulationcannothappenuntilthereisstabilityinthemethodsofworking,butthedevelopmentdoesn’tstandstill–clinicaltrialsaretakingplaceatthesametimeastheformulationisbeingdeveloped.Whatarewemaking?Theselectionofadosageformisnoteasy.Itbecomessimplerwhentheintendedproductisanextensionofanexistingline.ThisisverycommonintheOTCmarket(Over-the-Counter).YearsagoAnadin(orsimilarbrands)existedasonlyoneform.OTCItisnowcommontohaveco-existencebetweentablets,capsules,caplets,solubleforms,extended/modifiedreleaseformsofthesamebrandname.Formulationworktoextendintoanewareaisstillhard,butmuchlessdemandingthanformulatingatotallynewAPIintothefirstproduct.FactorsrelatingtochoiceofdosageformClinicalconcerns…whatisbeingtreated?,self-administeredproduct?Orforhospitaluse?Hospitalsmightuseinfusionsorivinjections.Physico-chemicalaspects…solubility,partitionbehaviour,pK/pHBioavailabilityMarketingaspectsmarketingMedicinesareproductsandaremadeinordertomakeprofitsforthecompany.Itisthussensibleformarketingconcernstohaveasayintheselectionofthedosageformforanewproduct.MarketingexpertslookattrendsinsalesandtheactivitiesofcompetitorsRoutes/propertiesSotheselectionofaproductisablendofdifferentdrivingforces.Evenwhenadosageformhasbeenselected,thereisstillthequestionofpotency.Theeffectivenessoftheproductwillhavebeentestedinclinicaltrials,andthesewillhaveshowntheneedforsay50,100,and250mgstrengthtablets,togetherwithsay,anoralsuspension.transportAgeneralfeatureisthatdrugsmustcrossepitheliallayerstoreachgeneralcirculation.Thisabilityisincreasedbyalargeconcentrationgradient,butalsobythecorrectphysico-chemicalproperties.Therateisthusaffectedbytheionizationstateofthedruganditslipid/aqueoussolubility.Reviselastterm’snotesAspectssuchtheHenderson-HasselbalchandlogPwerediscussedlastterm.ParticlesizeWeallknowsimplethingssuchasifwewanttodissolvesugaritisquickertouseicingsugarthancrystallisedlumpsugar.Themaindifferenceisparticlesize.Smallerparticlespresentalargerareatothesolventandhencedissolvemorerapidly.Whenusingaerosols(suchasinhalers)theparticlesizeisvital,toolargeandtheparticlesdonotreachthelungs–toosmallandtheyreach,butarealmostimmediatelyexhaled.micronization..meansreducingparticlestomicronsize(10-6m).Thisisoftenabrutalprocessandcaninduceotherphysicalchangesinthesubstanceorincreasethechanceofachemicalreactiontakingplace.Thisisanexampleofwherethefactorsrelatingtotheconductofaprocesshastobeinvestigated.Anotherexamplewouldbedrying.Removalofwatercanbedonebymanymethods,anditisalwayspossiblethatthemethodsusedinduceotheralterations.ThepatientThepatienthasaconsiderableinfluenceonthechoiceofroute.Localorsystemicaction?Rapidactionormediumtermaction?Complicatedregimen?Orasimpleonce-per-day?Age….childrenmayhaveswallowingproblems…h(huán)encemanysyrups(niceflavours)insteadofcapsules.3/12/202451RelatedChapters8:Physicochemicalproperties9:SolidStateProperties10:ParticleSizeAnalysis11:ParticleSizeReduction12:ParticleSizeSeparation13:PowderFlow24:PowdersandGranules25:Granulation26:Drying27:TabletandCompaction28:CoatingofTabletsandMultiparticulates29:HardGelatinCapsule30:SoftGelatinCapsule3/12/202452OralSolidDosageFormsPhysicochemicalCharacteristicsBiologicalCharacteristicsPharmaceuticalExcipientsPharmaceuticalManufacturingProcessStabilityProblemsofOralSolidDosageFormsBiopharmaceuticalConsiderations3/12/202453PhysicalCharacteristicsAppearanceTabletsCapsulesPowdersPhysicochemicalCharacterizationRapidReleaseSustained/ControlledReleaseEntericCoatingOtherCoating3/12/202454PhysicochemicalCharacteristicsThermodynamicallyStablePowderLessThermodynamicallyStableTabletCapsuleWhensomethingisthemodynamicallystable,itusuallymaintainsitsphysicalform.3/12/202455PhysicalCharacteristicsPowderSolidcoarsedispersionCapsulesPowdersGranulesCoatedgranulesTabletsSingleLayerMultipleLayers3/12/202456PhysicalCharacteristicsPowderApparenttasteApparentsmellCapsulesSlowerdrugreleaseLesstasteorsmellTabletsVariabledrugreleaserateSignificanttasteorsmell3/12/202457BiologicalCharacteristicsPowderRapidonsetofactionComplianceproblemCapsulesSloweronsetofactionSustaineddrugreleaseEasiertodosedrugswithbadtaste/smellTabletsComplianceproblemSloweronsetofaction3/12/202458PharmaceuticalExcipientsExcipientsdonothavepharmacologicalactivitiesthemselvesandshallnotenhanceordiminishthepharmacologicalactivitiesoftheactivespecies.Excipientsareusedinthemanufacturingorthecompoundingprocessforthepurposesof:MaintainingtheappearanceProtectingtheactivespeciesDisguisingtheunpleasanttaste/smellChangingthedissolutionratesofactivespecies3/12/202459PharmaceuticalExcipientsforPowdersMaintainingtheappearanceColorProtectingtheactivespeciesPreservativesAntioxidantsDisguisingtheunpleasanttaste/smellSugarFlavoringagentsMaintainingthevolumeDiluents3/12/202460PharmaceuticalExcipientsforCapsulesMaintainingtheappearanceColorCapsuleShellSealantsProtectingtheactivespeciesAntioxidantCoatingDisguisingtheunpleasanttaste/smellSealantsChangingthedissolutionratesofactivespeciesCoatingManufacturingDiluentsLubricantsGlidant3/12/202461TypesofCapsulesRegularCapsulesHardGelatinSoftGelatinControlledReleaseSystemsCoatedgranulesCoarsedispersion3/12/202462HardGelatinCapsule3/12/202463HardGelatinCapsule3/12/202464HandMadeGelatinCapsuleFillloadingtraywithemptycapsules.Placetrayinbed.Operatecamhandletoseparatecapsulescapfrombody.Placepowdertrayinposition,fillwithaccuratequantityofpowderandspreadwithscraper.Operatepinplatetocompressandfill.Operatelevertolockcapsulescapandbody.Removetrayandemptyfilledcapsules.3/12/202465HardGelatinCapsuleMachine/main.html3/12/202466SoftGelatinCapsule3/12/202467WorkingofSoftgelGelatinCapsuleMachine/softgel_manufacturing_process.htm3/12/202468SoftGelatinCapsuleMachine3/12/202469PharmaceuticalExcipientsforTabletsMaintainingtheappearanceColorConsistencyProtectingtheactivespeciesAntioxidantsDisguisingtheunpleasanttaste/smellSugarFlavoringagentsChangingthedissolutionratesofactivespeciesCoatingMatrixManufacturingDiluentsLubricantsGlidant3/12/202470TypesofExcipientsFiller/DiluentDisintegrantSolutionBinderDryBinderGlidantLubricantAntiadherentColorCoatingProtectiveAgents3/12/202471TabletManufacturingProcessMillingandGranulationProcess:Powdersand/orGranulesDrying:Reducemoisture/solventcontentEstablishstrongbondbetweensolidparticleswithinthegranulesSizingProcess:Maketheparticlesmoreuniform3/12/202472TabletManufacturingProcessMixingProcess:AddalltheexcipientstothemixersotheproducthasconsistencyandgoodflowcharacteristicsTablettingFillCompactionEjectionCoating:ProtectivecoatingPalatablecoating3/12/202473WeighingMixingGranulationTablettingCoatingDissolutionQAcheckQCCheckfrom:/tableting.htmTheTablettingProcess3/12/202474HandCrankedTabletMachine3/12/202475TabletMachine3/12/202476TabletPunchesandDies3/12/202477QualityAttributesofTabletsCorrectdoseConsistentweight,sizeandappearanceExpectedandreproduciblerateofdrugreleaseBiocompatible/SafeStrengthChemical,physically,andmicrobiologicallystableInvitecomplianceSafelypacked3/12/202478TabletCompactionGranulation:WetgranulatingDirectCompaction3/12/202479MakingTabletsviaGranulation
3/12/202480DirectCompaction3/12/202481RationaleforGranulationIncreasebulkdensityImproveflowabilityImprovehomogeneityImprovecompactabilityEnsurehomogenouscolorControldissolutionrate3/12/202482Tabletting
Process3/12/202483TablettingProcess3/12/202484MachineTablettingProcess3/12/202485TypesofExcipientsFiller/DiluentDisintegrantSolutionBinderDryBinderGlidantLubricantAntiadherentColorCoatingProtectiveAgents3/12/202486TabletExcipients-FillerFillerFunctions:Increasethebulkvolumesothatthefinalproducthasthepropervolumeforpatienthandling.FillerRequirements:inert,compatible,non-hydroscopic,soluble,cheap,compactable,tasteful(?)Fillers:Lactose,Sucrose,Glucose,Mannitol,Sorbitol,Calciumphosphate,Calciumcarbonate,Cellulose3/12/202487TabletExcipients-DisintegrantDisintegrantFunctions:Toensurethatwhentabletsareincontactwithwater,theyarerapidlybreakingintosmallerfragments,facilitatingtheirdissolutionDisintegrantTypes:
FacilitatewateruptakeRupturethetabletsDisintegrants:Starch,Cellulose,Crosslinkedpolyvinylpyrrolidone,SodiumStarchGlycolate,Sodiumcarboxymethylcellulose3/12/202488TabletExcipients-BinderBinderFunctions:ToensurethattabletsandgranulescanbeformedwithrequiredmechanicalstrengthBinderTypes:
DrypowderaddedtothemixturepriortothewetgranulationprocessSolutionthatisusedinthewetgranulationprocessAddrightbeforethetablettingprocessBinders:
Wet/SolutionBinders:Gelatin,Cellulose,Cellulosederivatives,Polyvinylpyrrolidone,Starch,Sucrose,PolyethyleneglycolDryBinders:Cellulose,Methylcellulose,Polyvinylpyrrolidone,PolyethyleneglycolNotlast……Itisfairlyobviousthatthechoiceofpackagingisamajorpartoftheproductdesign.Thepackagingistheexternalfaceoftheproductandisresponsibleforensuringtheintegrityoftheproduct.Thechoiceofthepackagingcomesearlyonintheproductdevelopmentcycle.Primaryetc…Primarypack–isindirectcontactwiththeproducte.g.ablisterpack.Secondarypack–holdstheprimarypacke.g.acardboardpack.Tertiarypack–holdsmultiplesecondarypackse.g.alargecardboardbox.PrimaryPackContainstheproduct.Givesimmediateprotectiontotheproduct.Reducesmechanicaldamage.Aidscompliance(calendarpacks)Reducesmaliciousdamage(tamper-proof)Stopsaccidentaluse(child-proof)BlisterpackTheblisterpackisoneofthemostcommonformsofprimarypackaging.Itcanofferprotectionfromlight,moisture,andmechanicalshock.Blistersarenotimperviousandmoisturecancross.Thenatureofthematerialsusedtoformthepackwillbeselectedaccordingtocompatibilitywiththeproduct.stabilityThestabilityofaproductisofmajorconcerntothemanufacturerandtothepharmacist.Allproductsdegrade–theissueisatwhatspeedandhencewhatistheshelf-life?Allstabilitytrialsonaproductareconductedwiththeproductinitsprimarypacking.CounterfeitproductsGenuineViagracomesinpacksoffour.Thecounterfeitproductshownherehasfiveperpack.CounterfeitinghereisquitesophisticatedandmakesprominentuseofthePfizerlogo.CalendarpacksThecontraceptive‘pill’isprobablythemainproductthatusescalendarpacksasanaidtotheuseoftheproduct.ChildproofprimarypackAblisterpackisnotchild-proof,Butmanyproductsdocomewithfeaturesthatmakeithardforyoungfingerstogainaccesstowhatmaylooklikesweets.Akeyfeatureofthedesignofchild-proofsystemsisthatvulnerableadultsarestillabletousetheproduct.Tamper-proofpacksTylenolwastheproductthatintroducedtamper-proofingtothepharmacy.TherewasanotoriouscaseintheUSwherepacksofTylenol(paracetamol)werecontaminatedwithapoisonandreplacedonsupermarketshelves.Theaimwasblackmail.Peopledied.Thefirmshrink-wrappingisagoodsigntotheuserthatthepackisinthesamestatethatitleftthefactory.VialsVialsareusedforsterileproducts.Specialconditionsareusedinthefillingofthesesystems.tubesTubesmaybemadeofplasticoraluminium.Theymustbeflexiblesothattheproductcanbeextruded.SecondarypackThesecondarypackhasanumberofobjectives:Oneimportantpointisthatitenablesauniformsizetobeproducedforeaseofputtingintothetertiarypack.Thesecondpointisthatitprovidesrecognitioninformationforthepharmacistandforthepatient.Itisalsoanimportantvehiclefordisplayofthecompanyimageandlogo.PackinsertsThesecondarypackistheidealplacetoaddothervitalpartsoftheprescribedmedicine.TheInformationLeafletismandatoryandcontainsessentialinformationforthepatient,suchastheingredients,whatconditiontheproductisdesignedtotreat,contra-indications,howtousetheproduct,warnings(‘donotdriveoroperatemachinery’etc.),storageadvice,expirydateetc.Otheritemsthatmaybeincludedcouldincludespoons,applicators,syringesetc.TertiarypackagingThesecondarypackswillbeputintosmallcartonsofasuitablesizeforuseinapharmacy.Thesetertiarypackswillbefurtherpackedintolargerunitssuitableforhandlingatthewarehouseandwholesalers(useofforklifttrucks).Theselargerunitswillbeshrink-wrappedinplasticandmayhavefurtherpackingtoensuresafetransportbyairetc.PackagingattheplantPackagingistheendoftheproductionprocess.Greatcarehastobetakentoensurethatthecorrectpackisusedsothatitmatchestheproductinallrespects.Asaprocessthisconcerns:PeopleEquipmentmaterialsPeopleAllstaffneedappropriatetrainingandmotivationtogetthisimportantworkdonecorrectly.Staffinvolved:OperatorsEngineers(mechanicalandelectrical0QCEquipmentPointstoconsider:Toobig?Toosmall?Easytoservice?Adaptable?Expensivecapitalcost?Expensivespareparts?WhyPK/PD?
?Provideasimplifieddescriptionoftheobservations?Importantindecisionmakingfordrugregulation?Canhelpsetdose,dosingintervalandclinicalefficacy?Complementclinicalendpointdatainmodifyingdosingregimes?Usefulinansweringresearchquestions(allADME)PK/PDmodels:Antibiotics?PD/PKdataisimportantindecidingwhicharetheimportantfactorsforefficacy/safetyissues?Eachdrugmayhavetobemodelledinadifferentway–Timedependent?T([plasma]>MIC)fora-lactams,macrolideantibiotics–Concentrationdependent?AUC/MICpredictiveforfluoroquinones?Cmax/MICforaminoglycosides–Canbeacombination!?GlycopeptidesFactors
referenceAulton‘Pharmaceutics’Secondedition(2002)pp113-138.PreformulationprogrammeWiderangeofpotentialdosageforms(addsomeexampleshere….Allwithsimilaraims StabilityReleaseofactiveDosageuniformityPurposeofprogrammeTomeasurephysicalandchemicalpropertiesoftheactiveagentinordertoguideTypeofformulationRouteofadministrationManufacturingprocessesTopicareasUVassay(spectroscopy)SolubilityPartitionMeltingbehaviourStability(heat/light/pHetc)MicroscopyPowderflowCompressionbehaviourExcipientcompatibilityLimitedquantitiesPreformulationisdonefairlyearlyintheproductdevelopmentcycle.Onlylimitedamountsofmaterialmaybeavailable.Veryaccuratemeasurementsarenotrequiredatthisstage.Manyprocesseshavebeenautomated.UVspectroscopyAlthoughthemajorityofactivepharmaceuticalsubstancesarewhitepowders,theymainlyhavespectroscopicactivityintheUVregionofthespectrum.Thisareacorrespondsinenergytovaluessimilartochemicalbondstrengths.Bestresultsareobtainedfrommoleculeswithdoublebonds.UVspectroscopyThespectrumhasapeakofmaximumabsorbance(inthiscaseat230nm).TheheightofthispeakisdirectlyproportionaltotheconcentrationofthesubstanceUseoftheUVspectrumAlthoughatypicalUVspectrumisofonlylimiteduseintheidentificationofasubstance,ithasgreatutilityasanassaymethod.SolubilitymeasurementThesolubilityofasubstanceisanimportantpropertythatdependsonthreefactors:ThenatureofthesubstanceThesolventThetemperaturesolubilityItisnormaltokeepthetemperatureconstantandforpharmaceuticalsubstancestousewaterasthesolvent–althoughthepHisalsorelevantandsometimestheionicstrengthofthesolutionaswell.Thebasicprincipleistoshakethesubstancewithwateruntilnomorewilldissolve.ThentheclearsolutionisfilteredoffandtheconcentrationmeasuredbyUVanalysis.Thiswillnormallyonlyworkifthesolutionisfirstdiluted.Thisisrelativelyeasywork–buttimeconsuming.Micro-titreplatesThepictureisofa96-well(12x8)micro-titreplate.ThewellscanbefilledbyroboticsandscannedbyalaserSolubilitybyroboticsStartwithasolutionofthesubstanceina‘super-solvent’(usuallydimethylsulfoxide).Addanamountofthissolutiontoeachwell.Thenaddincreasingamountsofwater(atafixedpH)tothewells.AtsomepointthesubstancewillcomeOUTofsolution.laserAlaserisshoneupthroughthesolution.Allthetimethereisasolutionthelightpassesstraightupwards.Whenthesubstancecomesoutofsolutionthelightwillbescatteredbytheparticles.Hencethesolubilitypointshowsup.HighthroughputscreeningSolubilitymeasurementasdescribedaboveisanexampleofhigh-throughputscreening.Themethodisreadilyadaptabletoproduceasolubilityprofile(asafunctionofpH)ofthedrugsubstanceItisalsopossibletousethesametechnologytomeasurethepKofweakacids.DeductionsfromsolubilitymeasurementsIdeallyadrugneedsabout1%aqueoussolubility(10mg/mL)ifpoorbioavailabilityproblemsaretobeavoided.Saltformationcanincreasesolubility.Or,formulateasaliquid-fillinsoftgelatincapsuleswiththedrugdissolvedinPEG400,glyceryltriacetate,orcoconutoil.SaltformationSaltsoftenhavegreateraqueoussolubilitythantheparentneutralmolecule.Butwhichsalttopick?ThisiswhereroboticsandHTScanhelp.Withsuitablechemistry,thedifferentpotentialsaltscanbeformedinawell-plateandtheirsolubilitymeasuredwithoutactuallymakingasolidsampleofthesalt.PartitionThefunnelshownhereisusedtoseparatetwolayers.Waterisnormallythelowerlayerandthelighterhydrocarbon-richsolventthetoplayer.Substancespartitionbetweenthetwolayersaccordingtotheirhydrophobiccharacter.Pharmaceuticallyweareinterestedinpartitionbetweenwater(atdifferentpHs)andoctanol.Themeasurementscanbemadebythe‘shake-the-flask’method(Aultonpp119-120)orbyanadaptationofthehigh-throughputsolubilitymethod.partitionPartitionisacrucialmeasurementforasubstance.Itrecordsthehydrophobic/hydrophilictendencyofthemolecule.Toohydrophobicanditwillhaveverylowaqueoussolubility.Toohydrophilicanditwillbeunabletocrossthemainlyhydrophobicmembranebarriersinthebody.MeltingbehaviourThemeltingpointofasubstanceisacharacteristicpropertythatisalsoanindicatorofpurity.Meltingisanexampleofaphase-change.Heatingcanalsoinducereactionsanddecomposition.MeltingpointmeasurementTheuseofstandardlaboratorymeasurementofthemeltingpointisquitetimeconsuming.Thereisalotofskillneededtogetreproducibleresults.Theenergychangethataccompaniesmeltingcanbeusedasamorereliablemethod.Italsorecordsanyotherphasechangesandanyreactions.DifferentialScanningCalorimetryThedifferentialscanningcalorimeterhastwocompartmentsthatareheatedseparately.Circuitryisusedtokeepthesametemperature.Whensomethinghappensinthesamplecompartmentthathasanenergychangethenthiscanbeprintedout.DSCtraceDSCTheDSCrecordsthermaleventsasthetemperatureisgraduallyraised.Itshowsphasechanges,reactionsandalleventsthatinvolveenergychanges.TheDSCtraceofadrugandmixtureswithpotentialexcipientswillshowwhethertherearelikelyreactionsbetweenthesubstances.Similartracescanberunoftheproductwithpotentialpackagingmaterials.PolymorphismPoly(‘many’)morphic(‘shape’)hencemanyshapes.Mostsubstanceshaveonlyonestablesolidform.Somesubstance
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 環(huán)境衛(wèi)生健康風險評估與治理策略
- 乙炔壓力表項目可行性分析報告范文
- 廣東開放大學2025年秋學期《社會調查研究與方法》形成性考核(含參考答案)
- 年產xxx內外墻磚項目可行性分析報告
- 網絡作家創(chuàng)作方向面試題庫
- 特殊人群知情同意的文化差異與適應策略
- 提升機項目可行性分析報告范文(總投資16000萬元)
- 深度解析(2026)《GBT 18487.4-2025電動汽車傳導充放電系統(tǒng) 第4部分:車輛對外放電要求》
- 核安全檔案數(shù)據(jù)云點播產品總監(jiān)面試題及答案
- 高鐵列車員職業(yè)技能等級認定模擬題集
- 礦山生態(tài)修復工程驗收規(guī)范
- 法律診所(第三版)課件全套 第1-10章 入門、會見-調解
- QC工作流程圖模板
- 電梯維保服務投標方案
- 4繼電控制線路故障檢測與排除
- 國家開放大學《公共部門人力資源管理》期末機考資料
- 大學生職業(yè)規(guī)劃與就業(yè)指導知到章節(jié)答案智慧樹2023年廣西中醫(yī)藥大學
- GB/T 20969.2-2021特殊環(huán)境條件高原機械第2部分:高原對工程機械的要求
- PMBOK指南第6版中文版
- 快速記憶法訓練課程速讀課件
- 步戰(zhàn)略采購方法細解 CN revison 課件
評論
0/150
提交評論